Proton

Atlantic Health System and Mevion Announce Plans to Bring Newest Proton Therapy Technology to Cancer Patients

Retrieved on: 
tisdag, juni 11, 2024
Nursing, Medical Devices, Hospitals, Health Technology, Practice Management, Radiology, Managed Care, Health, Oncology, Proton, Magnet, Head, News, Multimedia, Patient, Proton therapy, National Cancer Institute, Translational Genomics Research Institute, Research, Doctor of Philosophy, Senior, Bed, Physician, Morristown Medical Center, Malnutrition, Elective surgery, Pulmonology, Heart, Atlantic Health System, Breast, LINAC, Intensity, Survival, Neoplasm, Partnership, FIT, MLC, Scan (company), RN, Castle Connolly Medical, Carol, Cancer, Medical imaging

Atlantic Health System, an integrated health care system setting standards for quality health care in New Jersey, Pennsylvania and the New York metropolitan area, and Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, have announced Atlantic Health System’s plans to acquire and install a MEVION S250-FIT Proton Therapy System™* at the Carol G. Simon Cancer Center, located at Morristown Medical Center in New Jersey.

Key Points: 
  • Atlantic Health System, an integrated health care system setting standards for quality health care in New Jersey, Pennsylvania and the New York metropolitan area, and Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, have announced Atlantic Health System’s plans to acquire and install a MEVION S250-FIT Proton Therapy System™* at the Carol G. Simon Cancer Center, located at Morristown Medical Center in New Jersey.
  • The FIT Proton Therapy System is the first and only full proton therapy system that can be seamlessly installed in an existing LINAC vault, significantly reducing the size, cost, and complexity of proton therapy.
  • “We are excited to collaborate with Atlantic Health System in bringing the FIT proton therapy system to New Jersey,” said Tina Yu, PhD, CEO and President of Mevion Medical Systems.
  • We look forward to the positive impact this collaboration will bring to Morristown and its cancer patients.”
    *The MEVION S250-FIT Proton Therapy System is not yet available for clinical use.

New Clinical Research Provides Evidence that Proton Therapy Offers Significant Patient Benefits for Head and Neck Cancer Treatment

Retrieved on: 
onsdag, juni 5, 2024
Oncology, Health, Other Science, General Health, Clinical Trials, Research, Science, Proton, Head, NAPT, National Association, Proton therapy, Standard of care, Radiation therapy, Toxicity, Patient, NCCN, Malnutrition, Society, Education, MD Anderson Cancer Center, ASCO, NCI, Insurance, University, Medical imaging

Patients requiring radiation therapy for head and neck cancer benefit from proton therapy based on preliminary data from a multi-institution Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center .

Key Points: 
  • Patients requiring radiation therapy for head and neck cancer benefit from proton therapy based on preliminary data from a multi-institution Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center .
  • , professor of Radiation Oncology and executive director of the Particle Therapy Institute at The University of Texas MD Anderson Cancer Center.
  • The trial concluded that proton therapy was effective while producing fewer side effects, emerging as the standard of care treatment that reduces malnutrition and gastrostomy-tube dependence.
  • “This pivotal trial provides level-one evidence supporting the use of proton therapy for head and neck cancer and demonstrates the positive impact proton therapy can have on a patient’s health during and after treatment,” said Director Jennifer Maggiore, executive director of the National Association for Proton Therapy (NAPT).

IHH reports highest ever quarterly revenue in Q1 2024, with double-digit growth across key metrics, on outstanding performance across all markets

Retrieved on: 
onsdag, maj 29, 2024
Proton, Finance, Patient, ACE, IHH, ROE, Sale, International Medical University, Proton therapy, Bed, Annual general meeting, Bank

Highest ever quarterly revenue; revenue and EBITDA saw double-digit growth from sustained patient volume and taking on more acute, complex cases.

Key Points: 
  • Highest ever quarterly revenue; revenue and EBITDA saw double-digit growth from sustained patient volume and taking on more acute, complex cases.
  • PATMI excluding exceptional items (“PATMI (ex EI)”) was up 22% on the strong operational performance.
  • Balance sheet remained strong: net cash generated from operating activities at RM831.3 million; overall cash balance at RM2.2 billion.
  • 1 The Group’s headline performance includes the application of the MFRS 129 accounting standard (Financial Reporting in Hyperinflationary Economies) relating to its entities in Türkiye.

Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH

Retrieved on: 
tisdag, maj 21, 2024
Proton, Principal, Bangladesh Technical Education Board, Patient, Pharmacokinetics, MASH, Liver, Liver disease, University, Doctor of Philosophy, Therapy, Armed Forces Medical College, SAN, MBA, UCSD, MD, NIDDK, Magnetic resonance, NAFLD, Magnetic resonance imaging, Division, Digestive, Safety, Kidney, University of California, Hepatology, NIH

SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has completed enrollment in the ALG-055009 Phase 2a HERALD study for metabolic dysfunction-associated steatohepatitis (MASH) with topline safety and efficacy data anticipated in early Q4 2024. The company also announced that Dr. Rohit Loomba will serve as Principal Investigator for the study.

Key Points: 
  • The company also announced that Dr. Rohit Loomba will serve as Principal Investigator for the study.
  • “Completing enrollment in our first Phase 2a trial is a tremendous accomplishment for the Aligos team,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics.
  • In addition, I’d like to welcome Dr. Rohit Loomba as our Principal Investigator for the HERALD study.
  • “The excellent potency and PK profile makes ALG-055009 a compelling potential treatment option for MASH patients.

Plug Signs 3 GW BEDP Contract with Allied Green Ammonia for Electrolyzer Project in Australia

Retrieved on: 
torsdag, maj 16, 2024
Proton, PEM, FEED, FID, Growth, Front-end engineering, SMR, Steam, Plug, Ammonia, TPD, Renewable energy

The FID for AGA’s hydrogen-to-ammonia facility, with a capacity of 2,700 metric ton-per-day (TPD) green ammonia, is planned for Q4 2025.

Key Points: 
  • The FID for AGA’s hydrogen-to-ammonia facility, with a capacity of 2,700 metric ton-per-day (TPD) green ammonia, is planned for Q4 2025.
  • “Moving this major green hydrogen-to-ammonia project to the BEDP phase is a sign of its maturity in the development process,” noted Plug CEO Andy Marsh.
  • This BEDP agreement is a significant milestone in the development of Allied Green’s facility, which will be one of the most efficient green hydrogen and green ammonia projects globally.
  • This announcement follows Plug’s recently announced BEDP contracts totaling 4.5 GW, bringing Plug’s total BEDP contracts to 7.5 GW to date spanning across the United States, Europe and Australia.

IHH Spearheads Cancer Care Leadership in Asia With Official Launch of Region’s First Private Proton Therapy Centre

Retrieved on: 
onsdag, maj 15, 2024
Proton, Patient, System, IHH, Center of excellence, IHH Healthcare, Cancer, Proton therapy, MNH, Tissue, Quality of life, Medical imaging

Centre has already treated more than 100 patients from 16 countries, ranging in ages from 18 months to 85 years.

Key Points: 
  • Centre has already treated more than 100 patients from 16 countries, ranging in ages from 18 months to 85 years.
  • SINGAPORE, May 15, 2024 (GLOBE NEWSWIRE) --  IHH Healthcare, a world-leading integrated healthcare provider, has reinforced its position as Asia’s leading cancer care provider with the official opening of the Mount Elizabeth Proton Therapy Centre in Singapore.
  • Located in Mount Elizabeth Novena Hospital, the centre makes IHH the first private healthcare provider in the region and in Singapore to offer proton therapy, providing patients unprecedented access to this advanced and highly specialised cancer treatment.
  • IHH Healthcare Singapore’s investment in proton therapy demonstrates our unwavering resolve to provide our patients with the best care,” said Dr Peter Chow, Chief Executive Officer, IHH Healthcare Singapore.

Xspray to present data at ASCO highlighting frequent comedication of PPIs with TKIs in CML-patients and greater than expected negative effects on the bioavailability of crystalline dasatinib

Retrieved on: 
torsdag, maj 23, 2024
Oncology, Health, Other Science, Clinical Trials, Science, Pharmaceutical, Biotechnology, Proton, Acute leukemia, Patient, TKI, PPI, Prescription, CML, Karolinska Institute, Proton-pump inhibitor, Cmax, Enzyme inhibitor, Teaching hospital, Effect, Absorption, Tablet, Chronic myelogenous leukemia, Omeprazole, Combination therapy, Cancer, ASCO, Uppsala University, Society, NT, Dasatinib, Annual general meeting, Pharmaceutical industry

Of those prescribed a PPI, 66% of the prescriptions were by a different healthcare provider.

Key Points: 
  • Of those prescribed a PPI, 66% of the prescriptions were by a different healthcare provider.
  • Further, the presentation provides new information on the bioavailability of crystalline dasatinib when comedicated with a PPI, demonstrating a substantially higher than previously reported impact of PPIs on the bioavailability of crystalline dasatinib, with Cmax and AUC24 being reduced by 96% and 88% respectively.
  • “Consistent absorption and bioavailability of dasatinib are critical for adequate disease control and patient outcomes, this is however often overlooked in clinical practice as our data demonstrates,” said Per Andersson, CEO of Xspray.
  • Frequency of Comedication of Proton Pump Inhibitors with Crystalline Dasatinib in Chronic Myeloid Leukemia and Effects on TKI-Bioavailability.

Ohmium Selected to Provide 10MW PEM Electrolyzers for First Green Hydrogen Project in Croatia

Retrieved on: 
måndag, maj 20, 2024
Technology, Engineering, Transportation, Travel, Manufacturing, Environmental Policy, Alternative Vehicles, Fuels, Automotive, Alternative Energy, Energy, Environment, Sustainability, Semiconductor, Green Technology, Proton, Hydrogen, Partnership, Transport, PEM, Proton-exchange membrane, INA, International, Multimedia, Renewable energy

Ohmium International (“Ohmium”), a leading green hydrogen company that designs, manufactures, and deploys advanced Proton Exchange Membrane (PEM) electrolyzers, is pleased to announce that it was selected to equip the first green hydrogen project in Croatia.

Key Points: 
  • Ohmium International (“Ohmium”), a leading green hydrogen company that designs, manufactures, and deploys advanced Proton Exchange Membrane (PEM) electrolyzers, is pleased to announce that it was selected to equip the first green hydrogen project in Croatia.
  • Ohmium was selected to serve as the PEM electrolyzer supplier for IVICOM, a leading Croatian engineering and construction company, on a project to build a 10MW green hydrogen plant at the INA Rijeka Refinery.
  • View the full release here: https://www.businesswire.com/news/home/20240520820657/en/
    INA Rijeka Refinery in Kostrena, Croatia (Photo: Business Wire)
    The project will pair Ohmium’s PEM electrolyzers with a new solar power plant to produce green hydrogen to help decarbonize INA’s Rijeka Refinery and supply sustainable fuel for Croatia’s growing transportation market.
  • “This partnership is in line with our company vision of prioritizing green projects and green hydrogen innovation for a sustainable future.”
    “The green hydrogen installation at the Rijeka Refinery will be a premier example of the green transition in Europe,” said Arne Ballantine, Ohmium CEO.

Ohmium Collaborates with HYGRO for 5.4MW Green Hydrogen and Wind Turbine Pilot Project in the Netherlands

Retrieved on: 
onsdag, maj 15, 2024
Environment, Other Energy, Engineering, Utilities, Oil, Gas, Sustainability, Alternative Energy, Manufacturing, Green Technology, Energy, Proton, Transport, PEM, Proton-exchange membrane, Wind, International, Electricity, European, Electronics, Renewable energy

Ohmium International (“Ohmium”), a leading green hydrogen company that designs, manufactures, and deploys advanced Proton Exchange Membrane (PEM) electrolyzers, is launching a collaboration with HYGRO, a Dutch provider of green hydrogen, beginning with a new hydrogen production and distribution project in North Holland.

Key Points: 
  • Ohmium International (“Ohmium”), a leading green hydrogen company that designs, manufactures, and deploys advanced Proton Exchange Membrane (PEM) electrolyzers, is launching a collaboration with HYGRO, a Dutch provider of green hydrogen, beginning with a new hydrogen production and distribution project in North Holland.
  • The innovative pilot project will pair Ohmium PEM electrolyzers with HYGRO wind turbines at the EWEF Wind Park in Wieringerwerf, producing green hydrogen for distribution to fueling stations throughout the region.
  • Co-locating the PEM electrolyzers with the wind turbines enables stable, consistent and reliable electricity supply to the grid, despite fluctuating wind conditions.
  • “Ohmium shares HYGRO’s vision for an integrated green hydrogen supply chain to foster a sustainable and fossil free future,” said Arne Ballantine, Ohmium CEO.

GIST Researchers Develop Nanotechnology for Creating Wafer-Scale Nanoparticle Monolayers in Seconds

Retrieved on: 
onsdag, maj 8, 2024
Doctor of Philosophy, Observation, Nanoparticle, Motivation, Assistant, Dicarboxylic acid, Proton, Diffusion, Painting, Nature, Research, Water, Advanced Materials, Environmental remediation

The unique abilities of nanoparticles make them lucrative materials for a wide range of applications both for research and industrial purposes.

Key Points: 
  • The unique abilities of nanoparticles make them lucrative materials for a wide range of applications both for research and industrial purposes.
  • While artificial methods struggle with these drawbacks, underwater adhesion processes found in nature have evolved into unique strategies to overcome this problem.
  • The researchers engineered the electrostatic surface potential for both the target surface and the nanoparticles, driven by proton dynamics.
  • The researchers further found that the charge-sensitive nature of the underlying process enables deterministic "healing" of monolayer films and "pick-and-place" nanopatterning at the wafer scale.